Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

BACKGROUND: Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the central nervous system that primarily afflicts young adults.Approximately 400,000 people in the United States are affected by MS.Although several forms of MS exist, the most common course is known as relapsing-remittin...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Lawrence, Edwards, Natalie C., Fincher, Contessa, Doan, Quan V., AL-Sabbagh, Ahmad, Meletiche, Dennis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437839/
https://www.ncbi.nlm.nih.gov/pubmed/19739877
http://dx.doi.org/10.18553/jmcp.2009.15.7.543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437839/
https://www.ncbi.nlm.nih.gov/pubmed/19739877
http://dx.doi.org/10.18553/jmcp.2009.15.7.543

Ejemplares similares